First US drug approved for a liver disease surging around the world

Heidi Ledford

DOI: https://doi.org/10.1038/d41586-024-00747-9

IF: 64.8

2024-03-16

Nature

Abstract:A therapy called resmetirom improves hallmarks of an obesity-linked condition that can lead to liver failure. A therapy called resmetirom improves hallmarks of an obesity-linked condition that can lead to liver failure.

multidisciplinary sciences

What problem does this paper attempt to address?

Resmetirom: The First Food and Drug Administration–Approved Medication for Nonalcoholic Steatohepatitis (NASH)

Erenie Guirguis,John Dougherty,Krisy Thornby,Yasmin Grace,Keri Mack

DOI: https://doi.org/10.1177/10600280241259528

IF: 3.4628

2024-06-20

Annals of Pharmacotherapy

Abstract:Annals of Pharmacotherapy, Ahead of Print. Objective:To review the literature leading to the Food and Drug Administration (FDA) approval of the first medication, resmetirom, for the treatment of nonalcoholic steatohepatitis (NASH), including the pharmacology, pharmacokinetics, clinical studies, dosing, and adverse effects. Relevant data will be used to discuss how resmetirom impacts clinical practice.Data sources:A literature search was conducted using MEDLINE from database inception to May 12, 2024. Keywords included non-alcoholic steatohepatitis, nonalcoholic fatty liver disease, and resmetirom. Study selection, data extraction and all English-language studies involving the use of resmetirom for nonalcoholic fatty liver disease (NAFLD)/NASH were included.Data synthesis:Resmetirom, a thyroid hormone receptor agonist, is administered at daily doses of either 80 mg or 100 mg. The drug was shown to provide NASH resolution as assessed by the NAFLD activity score, 80 mg-24.2%, 100 mg-25.9% compared to 14.2% with the placebo group (P < 0.001). Resmetirom, improved liver fibrosis, 80 mg-25.9%, 100 mg-29.9% compared to 9.7% with the placebo group (P < 0.001). Resmetirom's ability to improve fibrosis in patients with F2-F3 fibrosis offers valuable benefit for patients at risk of progressing to cirrhosis.Relevance to patient care and clinical practice:Resmetirom expands the medication options available to treat patients with NASH which can be given alongside other medications to optimize metabolic factors such as glucagon-like peptide-1 and hydroxymethylglutaryl-coenzyme A reductase inhibitors. Resmetirom was well tolerated in studies.Conclusion:Resmetirom serves as an attractive option in patients diagnosed with NASH with evidence of advanced fibrosis (F2-F3) in combination with exercise, diet, and other multimodal therapies targeting metabolic risk factors.

pharmacology & pharmacy
The first MASH drug therapy on the horizon: Current perspectives of resmetirom

Salvatore Petta,Giovanni Targher,Stefano Romeo,Utpal B. Pajvani,Ming‐Hua Zheng,Alessio Aghemo,Luca V. C. Valenti

DOI: https://doi.org/10.1111/liv.15930

IF: 8.754

2024-04-06

Liver International

Abstract:The rising prevalence of metabolic dysfunction‐associated steatotic liver disease (MASLD) poses a significant global health challenge, affecting over 30% of adults worldwide. MASLD is linked to increased mortality rates and substantial healthcare costs, primarily driven by its progression to metabolic dysfunction‐associated steatohepatitis (MASH), which can lead to severe liver complications including cirrhosis and hepatocellular carcinoma. Despite its growing burden, effective pharmacotherapy for MASLD/MASH has been lacking until the recent conditional approval of resmetirom by the FDA. Resmetirom, a liver‐targeted thyroid hormone receptor‐β selective drug, has shown promise in clinical trials for treating non‐cirrhotic MASH with moderate to advanced fibrosis. It has demonstrated efficacy in reducing hepatic fat content, improving liver histology (both MASH resolution and fibrosis improvement), and ameliorating biomarkers of liver damage without significant effects on body weight or glucose metabolism. Notably, resmetirom also exhibits favourable effects on circulating lipids, potentially reducing cardiovascular risk in MASLD/MASH patients. The safety profile of resmetirom appears acceptable, with gastrointestinal adverse events being the most common, though generally mild or moderate. However, long‐term surveillance is warranted to monitor for potential risks related to thyroid, gonadal, or bone diseases. Clinical implementation of resmetirom faces challenges in patient selection and monitoring treatment response, and will heavily rely on non‐invasive tests for liver fibrosis assessment. Nonetheless, resmetirom represents a landmark breakthrough in MASLD/MASH treatment, paving the way for future therapeutic strategies aiming to mitigate the multifaceted risks associated with this complex metabolic liver disease.

gastroenterology & hepatology
Ann Robinson's research reviews—15 February 2024

Ann Robinson

DOI: https://doi.org/10.1136/bmj.q366

2024-02-16

BMJ

Abstract:Resmetirom for non-alcoholic steatohepatitisThe global incidence of non-alcoholic fatty liver disease is estimated to be one in 20. About a fifth of cases will cause liver cell inflammation and damage known as non-alcoholic steatohepatitis (NASH). As NASH progresses to severe fibrosis and on to cirrhosis, the risk of death from liver disease increases. Lifestyle changes help early stage NASH, but there's no approved drug treatment as yet. This phase 3 trial is encouraging. Among 966 patients with NASH, resmetirom (80 mg and 100 mg doses)—an oral, liver-directed, thyroid hormone receptor agonist that reduces fibrosis—was more effective than placebo in resolution of NASH with no worsening of fibrosis (26% v 30% v 10%) and improving liver fibrosis (24% v 26% v 14%) over one year. Lipid profiles improved too, which is helpful as most of these patients with NASH also had diabetes and are at increased risk of cardiovascular disease. N...

medicine, general & internal
Resmetirom: First Approval

Susan J. Keam

DOI: https://doi.org/10.1007/s40265-024-02045-0

2024-05-22

Drugs

Abstract:Resmetirom (RezdiffraTM) is an oral thyroid hormone receptor-β (THR-β) agonist being developed by Madrigal Pharmaceuticals, Inc., to target the key underlying causes of metabolic dysfunction associated steatohepatitis (MASH) [previously known as nonalcoholic steatohepatitis (NASH)]. In March 2024, resmetirom was approved for use (under accelerated approval) in conjunction with diet and exercise for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in the USA. Resmetirom is also under regulatory review in the EU for the treatment of MASH/NASH. This article summarizes the milestones in the development of resmetirom leading to this first approval for the treatment of adults with MASH/NASH.

pharmacology & pharmacy,toxicology
NASH field celebrates 'hurrah moment' with a first FDA drug approval for the liver disease

Katie Kingwell

DOI: https://doi.org/10.1038/d41573-024-00051-1

IF: 112.288

2024-03-15

Nature Reviews Drug Discovery

Abstract:Madrigal's resmetirom has scored a landmark FDA win, bolstering hopes for a diverse pipeline of drugs for non-alcoholic steatohepatitis. Madrigal's resmetirom has scored a landmark FDA win, bolstering hopes for a diverse pipeline of drugs for non-alcoholic steatohepatitis.

pharmacology & pharmacy,biotechnology & applied microbiology
Resmetirom's Approval: Highlighting the Need for Comprehensive Approaches in NASH Therapeutics

Salah Abdalrazak Alshehade

DOI: https://doi.org/10.1016/j.clinre.2024.102377

IF: 3.189

2024-05-22

Clinics and Research in Hepatology and Gastroenterology

Abstract:The recent FDA approval of Rezdiffra (resmetirom), an oral partial agonist of the thyroid hormone receptor-beta (THR-beta), for the treatment of noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced fibrosis, has challenged conventional approaches to NASH drug development. Despite extensive efforts targeting typical pathways involved in NASH progression, such as lipogenesis, oxidative stress, and inflammation, these approaches have yet to yield any approved therapies. The success of resmetirom highlights the potential advantages of targeting THR-beta, which exerts pleiotropic effects on multiple pathways involved in NASH pathogenesis, including lipid metabolism, glucose homeostasis, and inflammation. In the phase 3 MAESTRO-NASH trial, resmetirom significantly improved NASH resolution, fibrosis, and LDL cholesterol levels compared to placebo, with a favorable safety profile. The tissue-specific action of resmetirom may also contribute to its efficacy and safety. The approval of resmetirom has opened new avenues for NASH drug development, emphasizing the importance of exploring novel mechanisms of action, developing targeted therapies, and embracing a more comprehensive approach to treatment. As the global burden of NASH continues to grow, the lessons learned from the success of resmetirom should inform future drug development strategies, offering hope to the millions of patients affected by this disease worldwide.

gastroenterology & hepatology
Opportunities and challenges following approval of resmetirom for MASH liver disease

Jeffrey V. Lazarus,Dana Ivancovsky Wajcman,Henry E. Mark,Zobair M. Younossi,Christopher J. Kopka,Nevin Cohen,Meena B. Bansal,Michael Betel,Paul N. Brennan

DOI: https://doi.org/10.1038/s41591-024-02958-z

IF: 82.9

2024-04-20

Nature Medicine

Abstract:The US Food and Drug Administration (FDA) has approved the first drug, resmetirom, for metabolic dysfunction-associated steatohepatitis (MASH), but much work remains for the industry, practitioners and health systems so that this approval will benefit all patients.

biochemistry & molecular biology,cell biology,medicine, research & experimental
Anti-malarial drug: the emerging role of artemisinin and its derivatives in liver disease treatment

Ye Xiong,Jianrong Huang

DOI: https://doi.org/10.1186/s13020-021-00489-0

IF: 4.546

2021-01-01

Chinese Medicine

Abstract:Artemisinin and its derivatives belong to a family of drugs approved for the treatment of malaria with known clinical safety and efficacy. In addition to its anti-malarial effect, artemisinin displays anti-viral, anti-inflammatory, and anti-cancer effects in vivo and in vitro. Recently, much attention has been paid to the therapeutic role of artemisinin in liver diseases. Several studies suggest that artemisinin and its derivatives can protect the liver through different mechanisms, such as those pertaining to inflammation, proliferation, invasion, metastasis, and induction of apoptosis and autophagy. In this review, we provide a comprehensive discussion of the underlying molecular mechanisms and signaling pathways of artemisinin and its derivatives in treating liver diseases. Further pharmacological research will aid in determining whether artemisinin and its derivatives may serve as promising medicines for the treatment of liver diseases in the future.
How improvements in US FDA regulatory process and procedures led to the drug approval for first ever treatment of a common liver disease

Brian E. Harvey

DOI: https://doi.org/10.1038/s41401-024-01396-4

IF: 7.169

2024-11-08

Acta Pharmacologica Sinica

Abstract:Metabolic-associated liver disease is a growing public health crisis, with phenotypes from fatty liver to steatohepatitis, previously known as NASH (Non-Alcoholic SteatoHepatitis) and currently rebranded as MASH (Metabolic dysfunction-Associated SteatoHepatitis). Dysfunction in liver metabolism can progress to liver fibrosis, end stage cirrhosis and death. MASH (NASH) is associated with an increased risk of cardiovascular disease, elevation in serum lipids and Type 2 Diabetes Mellitus. There is now a US-approved drug to treat patients with NASH (MASH) under the FDA Accelerated Approval Pathway, which requires follow-up outcome studies to confirm clinical benefit or risk drug withdrawal by the agency. Despite extra-hepatic factors that contribute to MASH and complicate clinical trial design, reorganization of the FDA drug premarket review divisions, improvements to agency policies and procedures, as well as updates to the US Food, Drug & Cosmetic Act (FD&C Act) upon which FDA regulation is based, have provided new agency tools that facilitated such a drug approval to address the profound unmet medical need for patients with this metabolic-based liver disease. There is reason for hope that continued evolution of the regulatory process will lead to additional drug approvals, as well as the ability for clinical trial endpoints studying MASH treatments to include both liver-based and traditional metabolic measures, independent of the specific FDA review division. This initial NASH/MASH FDA approval has also opened the door for initiation of Combination Clinical Trials, where the approved drug is paired with an experimental drug with a different mechanism of action, to increase overall efficacy and potentially minimize risks. It is envisioned that future treatment of NASH/MASH will mirror what is currently observed with Type 2 Diabetes Mellitus practice patterns, where multiple drugs with different mechanisms of actions are used to optimize treatment benefit/risk in the selected patient populations.

pharmacology & pharmacy,chemistry, multidisciplinary
Resmetirom: A Systematic Review of the Revolutionizing Approach to Non-alcoholic Steatohepatitis Treatment Focusing on Efficacy, Safety, Cost-Effectiveness, and Impact on Quality of Life

Parikshit Bittla,Sai Pavitra Paidimarri,Shriya Ayuthu,Yashkumar D Chauhan,Moyal Z Saad,Amna A Mirza,Safeera Khan

DOI: https://doi.org/10.7759/cureus.69919

2024-09-22

Cureus

Abstract:There has been a rise in the prevalence of non-alcoholic steatohepatitis (NASH), a subset of non-alcoholic fatty liver disease (NAFLD) with an ongoing increase in the prevalence of linked conditions such as obesity, type II diabetes mellitus, and metabolic syndrome. To date, there are no specific drugs that are approved for the treatment of NAFLD/NASH. With the recent discovery of association between subclinical hypothyroidism and NASH, various trials exploring treatment options for NASH using thyroid hormone derivatives led to the discovery of resmetirom (MGL-316) with high affinity to thyroid hormone receptors (THRs) targeting the liver. Following standardized guidelines, a systematic review was performed on the safety, efficacy, and other practical aspects of resmetirom in the treatment of NASH. Advanced search was carried out using the MeSH search strategy and appropriate keywords in major databases using various inclusion and exclusion criteria. The search was narrowed down to seven high-quality articles: four randomized control trials (RCTs), and three reviews to be included in the current study. The online database search yielded 62 articles, out of which six high-quality articles were selected to be included in the current systematic review after deleting duplicates and screening for irrelevant titles, and articles. Out of the three RCTs, two of them assessed the safety and efficacy of resmetirom, while the remaining RCT assessed the impact on health-related quality of life with resmetirom on patients with NASH. resmetirom (MGL-316) is a thyroid hormone derivative with high affinity to THRs targeting the liver and acts by improving mitochondrial oxidation, and lipophagy in the hepatic cell line. All the trials suggested in favor of resmetirom with a decrease in NASH fibrosis score by at least two points, along with reduction in hepatic fat content (minimum relative reduction of 20%), liver volume by 61%, improving secondary outcomes such as low-density lipoprotein-C, apolipoprotein-B, triglycerides, and hepatic enzymes with greater reduction in the study groups treated with higher doses of resmetirom with no significant increase in adverse events. Resmetirom was found to improve patient-reported outcomes, and thereby quality-adjusted life years (QALYs) in 12 weeks while being cost-effective compared to placebo at a willingness-to-pay threshold of US$100,000 up to a daily threshold of US$72.00, and an effective incremental cost-effectiveness ratio of US$53,925 per QALY gained. After carefully analyzing the available data by our team members, it could be concluded that resmetirom holds a strong potential to be implemented as a drug of choice in treating NAFLD/NASH in the coming years with proven efficacy, safety while being cost-effective, and also reducing secondary co-morbidities by improving cardiovascular risk factors. The results can be best achieved when combined with conventional approaches such as weight loss and dietary modifications. Long-term safety and sustainability of the achieved results are yet to be confirmed with large-scale clinical trials. However, resmetirom is still an investigational drug and could be expected to be available for clinical practice in the near future.
FDA approves first MASH drug

DOI: https://doi.org/10.1038/s41587-024-02220-4

IF: 46.9

2024-04-18

Nature Biotechnology

Abstract:The first drug to treat fatty liver disease due to metabolic dysfunction-associated steatohepatitis (MASH) has been given a green light by the US Food and Drug Administration. Madrigal Pharmaceuticals' Rezdiffra (resmetirom) received an accelerated approval to treat the disease, previously known as non-alcoholic steatohepatitis (NASH). In this progressive liver condition fat buildup triggers inflammation and cell damage, leading to fibrosis and eventually cirrhosis. The complex pathophysiology of the condition and need for long-term safety have until now hindered drug discovery efforts. Rezdiffra is an oral thyroid hormone receptor-β (THR-β) agonist that improves lipid metabolism and mitochondrial activity in liver cells. The FDA's go-ahead was based in part on a phase 3 trial published in the New England Journal of Medicine . Biopsy samples from over 900 people showed that fat buildup and inflammation cleared without worsening fibrosis in 25% of patients at 12 months, compared with approximately 10% on placebo. In addition, fibrosis improved without worsening fatty liver symptoms in around 25% of patients, compared with 14% of patients in the placebo group. The drug also improved low-density lipoprotein cholesterol levels.

biotechnology & applied microbiology
Efficacy and safety of resmetirom among patients with non-alcoholic steatohepatitis: a systematic review and meta-analysis

Saad Mazhar,Aima Azhar,Ariba Khan,Gulrukh Shakil,Sapna Kumari,Deepa Devi,Sayed Jawad

DOI: https://doi.org/10.1097/MS9.0000000000002314

2024-07-15

Abstract:Background: Non-alcoholic steatohepatitis (NASH) is a severe medical illness that has few available therapeutic options. Resmetirom, a liver-targeting agonist of the thyroid hormone receptor (THR), has recently been licenced by the FDA. We assess the effectiveness and safety of resmetirom in patients with NASH. Methods: PubMed, SCOPUS and Cochrane Central were searched till March 2024 to find potential articles. Outcomes assessed included MRI-proton density fat fraction (MRI-PDFF), Fat Reduction, and NASH Resolution Without Fibrosis, changes in aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (GGT), low-density lipoprotein (LDL), and triglyceride (TG) levels, along with diarrhoea, nausea, urinary tract infection (UTI), and headache. Subgroup analysis was performed between outcomes before and after 6 months. Outcomes were analyzed with a random-effects model and results presented as mean difference (MD) for continuous outcomes and odds ratios (OR) for safety analysis, along with their 95% confidence intervals. A risk of bias assessment was performed using Cochrane Risk of Bias tool. Results: Four randomized controlled trials (RCTs) were included in our analysis. Resmetirom shown a substantial improvement in MRI-PDFF with a MD of -19.23 (P<0.00001). Additionally, it resulted in a 30% reduction in fat (OR: 3.54, P=0.004) and resolution of NASH without fibrosis (OR: 2.41, P=0.04). There was no notable enhancement observed in AST levels, with a mean difference of -0.87 and a P value of 0.73. The usage of resmetirom resulted in significant improvement in ALT levels (MD: -4.36, P value: 0.32), GGT levels (MD: -17.87, P value: <0.00001), TG levels (MD: -23.48, P value: <0.00001), LDL levels (mean difference: -12.80, P value: <0.00001), and rT3 levels (MD: -2.08, P value: <0.00001). The use of Resmetirom was associated with a higher likelihood of experiencing diarrhoea (OR: 2.07, P<0.0001) and nausea (OR: 1.81, P=0.0003). However, there was no significant difference observed in the occurrence of UTI (OR: 1.04, P=0.85) or headaches (OR: 0.79, P=0.48). Conclusion: Resmetirom demonstrates efficacy in enhancing MRI-PDFF score, diminishing adipose tissue, resolving NASH without fibrosis, reducing GGT, TG, LDL, reverse triiodothyronine (rT3) levels in NASH patients. Nevertheless, there is also an observed heightened susceptibility to experiencing diarrhoea and nausea. Additional trials are necessary to further examine the efficacy and safety of this medication.
Beyond resmetirom approval for NAFLD: what has to be done?

Devaraj Ezhilarasan

DOI: https://doi.org/10.1016/j.drudis.2024.104185

IF: 8.369

2024-09-22

Drug Discovery Today

Abstract:Drug Discov Today . 2024 Sep 18:104185. doi: 10.1016/j.drudis.2024.104185. Online ahead of print. NO

pharmacology & pharmacy
S2011 Real-World Characteristics of the Patients With Metabolic Dysfunction-Associated Steatohepatitis Prescribed Resmetirom: Data Derived From Two Tertiary Care Centers in the United States

Eda Kaya,Rida Nadeem,Himanshi Kapoor,Niharika Samala,Yusuf Yilmaz,Naim Alkhouri

DOI: https://doi.org/10.14309/01.ajg.0001037412.40234.5d

2024-10-26

The American Journal of Gastroenterology

Abstract:Resmetirom, recently FDA-approved, is the first drug for metabolic dysfunction-associated steatohepatitis (MASH) and at least stage F2 fibrosis. The approval was based on histological improvement in the phase 3 using liver biopsy for patient selection. However, in clinical practice, most MASH diagnosis rely on noninvasive tests rather than liver biopsies. Here, we aimed to describe the general characteristics and NITs of the MASH patients prescribed resmetirom from 2 hepatology clinics in the United States.

gastroenterology & hepatology
Safety and efficacy of resmetirom in the treatment of patients with non-alcoholic steatohepatitis and liver fibrosis: a systematic review and meta-analysis

Adarsh Raja,Raja Subhash Sagar,Sadia Saeed,Amna Zia Ul Haq,Owais Khan,Parshant Dileep Bhimani,Sandesh Raja,Fnu Deepak,Muhammad Ahmed,Muhammad Ashir Shafique,Muhammad Saqlain Mustafa,Muhammad Sohaib Asghar,Varsha Sharma

DOI: https://doi.org/10.1097/MS9.0000000000002195

2024-05-22

Abstract:Introduction: Non-alcoholic fatty liver disease (NAFLD), spanning from non-alcoholic steatohepatitis (NASH) to liver fibrosis, poses a global health challenge amid rising obesity and metabolic syndrome rates. Effective pharmacological treatments for NASH and liver fibrosis are limited. Objective: This study systematically reviews and meta-analyzes the safety and efficacy of resmetirom, a selective thyroid hormone receptor-β agonist, in NASH and liver fibrosis treatment. By analyzing data from clinical trials, we aim to offer evidence-based recommendations for resmetirom's use in managing these conditions and identify avenues for future research. Methods: Electronic databases (PubMed, Scopus, Science Direct, Google Scholar, ClinicalTrials.gov, and Cochrane CENTRAL) were systematically searched, supplemented by manual screening of relevant sources. Only English-language randomized controlled trials were included. Data extraction, risk of bias assessment, pooled analyses, and meta-regression were performed. Results: Three randomized controlled trials involving 2231 participants were analyzed. Resmetirom demonstrated significant reductions in hepatic fat fraction [standardized mean difference (SMD) -4.61, 95% CI -6.77 to -2.44, P < 0.0001], NASH resolution without worsening fibrosis [risk ratio (RR) 2.51, 95% CI 1.74-3.64, P = 0.00001), and liver fibrosis improvement (RR 2.31, 95% CI 1.20-4.44, P = 0.01). Secondary outcomes showed significant improvements in lipid profiles, liver enzymes, and NASH biomarkers with resmetirom treatment. Meta-regression revealed associations between covariates and primary outcomes. Conclusion: Resmetirom exhibits promising efficacy in reducing hepatic fat, improving NASH resolution, and ameliorating liver fibrosis with a favorable safety profile. Further research is warranted to validate findings and optimize therapeutic strategies for NASH and liver fibrosis management.
Liver-specific thyroid hormone receptor-β agonism alleviates alcoholic steatohepatitis (ASH) in mice

Ambuj Shahi,Abhishek Yadav,Sangam Rajak,Sana Raza,Archana Tewari,Pratima Gupta,Rohit A Sinha

DOI: https://doi.org/10.1016/j.bbrc.2024.150742

2024-11-19

Abstract:Alcoholic steatohepatitis (ASH) represents a critical stage in alcoholic liver disease (ALD), which significantly increases the risk of developing alcoholic hepatitis and cirrhosis. Currently, corticosteroids and alcohol abstinence remain the only available strategy to prevent or reverse ASH progression with no FDA approved drug therapy till date. Given the notable pathological similarities between ASH and metabolic dysfunction-associated steatohepatitis (MASH), repurposing drugs approved for MASH presents an attractive therapeutic approach to treat ASH. In this context, we evaluated the efficacy of Resmetirom, a recently approved drug for MASH, in a mouse model of ASH. Our findings demonstrate that Resmetirom, a liver-specific thyroid hormone analog, not only reduces hepatic steatosis but also markedly alleviates liver injury, oxidative stress, and inflammation associated with ASH. In summary, this study provides a proof-of-concept for the potential use of MASH drugs in treating ASH and establishes a foundation for future testing and clinical trials of Resmetirom, in patients with ASH.
Estimation of the Eligible Population For Resmetirom Among Adults in the United States for Treatment of Non-Cirrhotic NASH with Moderate-to-Advanced Liver Fibrosis

Bercaw, Eric M.

DOI: https://doi.org/10.1007/s12325-024-02989-5

2024-09-19

Advances in Therapy

Abstract:As of March 2024, resmetirom is the first and only therapy approved in the United States (US) for the treatment of adults with non-cirrhotic nonalcoholic steatohepatitis (NASH) with moderate-to-advanced liver fibrosis (MALF) consistent with stages F2/F3 fibrosis. Estimates of the diagnosed, treatment-eligible NASH population are poorly understood due to diagnostic variability. This study provides a contemporary estimate of the size of the US resmetirom treatment-eligible population.

pharmacology & pharmacy,medicine, research & experimental
Resmetirom proves positive for NASH with liver fibrosis

Katrina Ray

DOI: https://doi.org/10.1038/s41575-024-00909-0

2024-02-16

Nature Reviews Gastroenterology & Hepatology

Abstract:Positive phase III results have been reported for resmetirom (a thyroid hormone receptor β-selective agonist) for the treatment of nonalcoholic steatohepatitis (NASH; also known as metabolic dysfunction-associated steatohepatitis (MASH)) with liver fibrosis. In a phase III, randomized controlled trial, 966 patients with biopsy-confirmed NASH and liver fibrosis (stage F1B, F2 or F3) were randomly assigned to receive a once-daily dose of 80 mg resmetirom, 100 mg resmetirom or placebo for 52 weeks. Resolution of NASH with no worsening of fibrosis was achieved in 25.9% of the 80 mg group and 29.9% of the 100 mg group, compared with 9.7% in the placebo group ( P < 0.001 for both comparisons). Improvement in fibrosis by at least one stage with no worsening of disease activity scores occurred in 24.2% of the 80 mg group and 25.9% of patients in the 100 mg group, versus 14.2% in the placebo group ( P < 0.001 for both comparisons). Moreover, LDL cholesterol levels were also reduced by resmetirom (from baseline to week 24, –13.6% in the 80 mg group, –16.3% in the 100 mg group, 0.1% in the placebo group; P < 0.001).

gastroenterology & hepatology
Hepatic thyroid hormone receptor-β signalling: Mechanisms and recent advancements in the treatment of metabolic dysfunction-associated steatohepatitis

Stergios A Polyzos,Giovanni Targher

DOI: https://doi.org/10.1111/dom.16117

2024-12-10

Abstract:The pharmacotherapy of metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, the metabolic dysfunction-associated steatohepatitis (MASH), remains a hot topic in research and a largely unmet need in clinical practice. As the first approval of a disease-specific drug, resmetirom, was regarded as a milestone for the management of this common liver disease, this comprehensive and updated review aimed to highlight the importance of the hepatic thyroid hormone (TH) receptor (THR)-β signalling for the treatment of MASH, with a special focus on resmetirom. First, the genomic and non-genomic actions of the liver-directed THR-β mediated mechanisms are summarized. THR-β has a key role in hepatic lipid and carbohydrate metabolism; disruption of THR-β signalling leads to dysmetabolism, thus promoting MASLD and possibly its progression to MASH and cirrhosis. In the clinical setting, this is translated into a significant association between primary hypothyroidism and MASLD, as confirmed by recent meta-analyses. An association between MASLD and subclinical intrahepatic hypothyroidism (i.e. a state of relatively low hepatic triiodothyronine concentrations, with circulating TH concentrations within the normal range) is also emerging and under investigation. In line with this, the favourable results of the phase 3 placebo-controlled MAESTRO trials led to the recent conditional approval of resmetirom by the US FDA for treating adults with MASH and moderate-to-advanced fibrosis. This conditional approval of resmetirom opened a new window to the management of this common and burdensome liver disease, thus bringing the global scientific community in front of new perspectives and challenges.

First US drug approved for a liver disease surging around the world

Resmetirom: The First Food and Drug Administration–Approved Medication for Nonalcoholic Steatohepatitis (NASH)

The first MASH drug therapy on the horizon: Current perspectives of resmetirom

Ann Robinson's research reviews—15 February 2024

Resmetirom: First Approval

NASH field celebrates 'hurrah moment' with a first FDA drug approval for the liver disease

Resmetirom's Approval: Highlighting the Need for Comprehensive Approaches in NASH Therapeutics

Opportunities and challenges following approval of resmetirom for MASH liver disease

Anti-malarial drug: the emerging role of artemisinin and its derivatives in liver disease treatment

How improvements in US FDA regulatory process and procedures led to the drug approval for first ever treatment of a common liver disease

Resmetirom: A Systematic Review of the Revolutionizing Approach to Non-alcoholic Steatohepatitis Treatment Focusing on Efficacy, Safety, Cost-Effectiveness, and Impact on Quality of Life

FDA approves first MASH drug

Efficacy and safety of resmetirom among patients with non-alcoholic steatohepatitis: a systematic review and meta-analysis

Beyond resmetirom approval for NAFLD: what has to be done?

S2011 Real-World Characteristics of the Patients With Metabolic Dysfunction-Associated Steatohepatitis Prescribed Resmetirom: Data Derived From Two Tertiary Care Centers in the United States

Safety and efficacy of resmetirom in the treatment of patients with non-alcoholic steatohepatitis and liver fibrosis: a systematic review and meta-analysis

Liver-specific thyroid hormone receptor-β agonism alleviates alcoholic steatohepatitis (ASH) in mice

Estimation of the Eligible Population For Resmetirom Among Adults in the United States for Treatment of Non-Cirrhotic NASH with Moderate-to-Advanced Liver Fibrosis

Resmetirom proves positive for NASH with liver fibrosis

Hepatic thyroid hormone receptor-β signalling: Mechanisms and recent advancements in the treatment of metabolic dysfunction-associated steatohepatitis